J & J's Remicade losing ground in Quebec health plan despite court victory

Johnson& Johnson's Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec's public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news